Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SCPH | US
0.05
0.99%
Healthcare
Biotechnology
30/06/2024
30/08/2024
5.09
5.07
5.13
4.93
scPharmaceuticals Inc. a pharmaceutical company engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
54.9%1 month
76.7%3 months
76.9%6 months
72.6%-
-
27.58
4.47
0.63
-6.69
10.73
-
-60.36M
254.65M
254.65M
-
-179.18
-
391.70
-166.89
17.75
11.82
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.65
Range1M
1.44
Range3M
1.81
Rel. volume
0.37
Price X volume
642.56K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.86 | 277.80M | 3.62% | n/a | 137.55% |
CABALETTA BIO INC. | CABA | Biotechnology | 5.63 | 275.02M | -2.76% | n/a | 0.00% |
Enanta Pharmaceuticals Inc | ENTA | Biotechnology | 12.88 | 272.91M | -1.08% | n/a | 151.88% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 4.75 | 268.95M | 0.85% | n/a | 1.03% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 7.33 | 265.42M | -3.81% | n/a | 9.95% |
ChromaDex Corporation | CDXC | Biotechnology | 3.45 | 261.97M | 2.68% | n/a | 10.17% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6255 | 257.19M | 3.18% | n/a | 1.47% |
OBIO | OBIO | Biotechnology | 6.7 | 253.42M | 0.30% | n/a | 0.00% |
2seventy bio Inc | TSVT | Biotechnology | 4.87 | 250.79M | 1.04% | n/a | 107.07% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 5.7 | 246.89M | 2.52% | n/a | 31.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 15.53 | 251.70M | 1.70% | 9.96 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.42 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.69 | 0.97 | Cheaper |
Ent. to Revenue | 10.73 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 27.58 | 14.54 | Expensive |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 76.86 | 76.13 | Par |
Debt to Equity | 4.47 | -2.05 | Expensive |
Debt to Assets | 0.63 | 0.25 | Expensive |
Market Cap | 254.65M | 4.04B | Emerging |